to chronic disease
Oliver Siegel, CEO
Oliver is Chief Executive Officer at AFFiRiS since March 2015. He is responsible for operations, including clinical operations, finance and administration at AFFiRiS. Prior to joining AFFiRiS as Chief Operating Officer in 2014, Oliver was Managing Director and Head of Pharmaceuticals at leading Investment Bank NM Rothschild & Sons, London. He has more than 15 years of experience in leading Investment Banks Rothschild, HSBC, Merrill Lynch and Deutsche Bank on strategy and fundraising for Pharma, Biotechnology and Healthcare Services companies. Oliver holds a degree in business administration from Otto-Friedrich-University Bamberg.
Günther Staffler, CTO
Günther is Chief Technology Officer at AFFiRiS. He is responsible for Preclinical Development and Technology at AFFiRiS. Prior to his appointment to the Executive Board Günther led the Immunology Department. Prior to joining AFFiRiS Günther held various positions at Intercell and Biovertis which he co-founded. Günther completed his degree in biochemistry and immunology at the Institute for Immunology of University of Vienna and has authored many publications in international journals. He was awarded the “Förderungspreis” of the Austrian Society of Chemistry in 1996 and the “Ursula und Fritz Melcher’s Preis” of the Austrian Society of Immunology in 2003.